Efficacy and tolerability of abatacept treatment: results of 12 months observation.

Aim: This article reports 1-year clinical outcomes of patients with rheumatoid arthritis (RA) receiving abatacept (ABA) therapy.

Materials And Methods: Patients (n=91) with high RA activity (DAS28 = 5.1 ± 1.

Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis.

Introduction: An increasing body of evidence indicates that interferon (IFN )-gamma is an immunoregulator and may play a key role in the pathogenesis of autoimmune diseases, including rheumatoid arthritis (RA).

Objective: To assess the efficacy and tolerability of anti-IFN-gamma in patients with active RA.

Methods: In a randomized, double-blind trial, 30 patients with active RA were randomly assigned to receive intramuscular injections of anti-IFN-gamma, anti-TNF-alpha, or placebo for 5 consecutive days.